Business / Finance

RSS

ERBA Diagnostics’ net revenues increase 83% to $6,941,000 in third quarter 2013

ERBA Diagnostics, Inc., a fully integrated in vitro diagnostics company, reported its financial results for the three and nine months ended September 30, 2013.

11 Nov 2013

Cardioinsight completes long-term strategic financing to conclude multi-center clinical studies in Europe

CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.

11 Nov 2013

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

Chindex International, Inc., an American healthcare company providing healthcare services in China through the operations of United Family Healthcare, a network of private primary care hospitals and affiliated ambulatory clinics, today announced financial results for the third quarter of 2013 ended September 30, 2013.

11 Nov 2013

Lawnwood Regional Medical Center & Heart Institute buys first Renaissance system

Mazor Robotics Ltd., the developer of Renaissance, an innovative surgical guidance system and its complementary products, announced today that Lawnwood Regional Medical Center & Heart Institute, located in Ft. Pierce, FL, has purchased its first Renaissance system.

11 Nov 2013

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

ChinaSoft International Limited, announced that it has signed a strategic agreement with CITIC 21CN Company Limited on the Pharmaceutical Information Sharing Program.

11 Nov 2013

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Genovate Biotechnology Co. Ltd. and ScinoPharm Taiwan Ltd. announced today that they have jointly developed the highly potent oral generic drug Livepro (Entecavir), representing a new generation of drugs for the treatment of Hepatitis B. It is expected to be commercially available by the end of the year in Taiwan, accounting for more than NT$2 billion (US$70 million) worth of market opportunity.

11 Nov 2013

Covidien fourth quarter net sales increase 2% to $2.56 billion

Covidien plc today reported results for the fourth quarter of fiscal 2013 (July - September 2013). Fourth-quarter net sales of $2.56 billion increased 2% from the $2.50 billion in the fourth quarter a year ago. Foreign exchange rate movement lowered the quarterly sales growth rate by three percentage points.

8 Nov 2013

China Cord Blood Corporation releases financial results for second quarter and first half of fiscal year 2014

China Cord Blood Corporation (NYSE: CO) (the "Company") today announced its plan to release financial results for the second quarter and first half of fiscal year 2014 on Thursday, November 14, 2013, after market close in the US.

7 Nov 2013

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

ImmunGene, Inc., a biotechnology company focused on developing antibody-cytokine fusion technology therapies to treat cancer, today announced it has secured $9 million in a milestone-based Series A financing from Ally Bridge Group. Previous investments in the Company were converted into Series A preferred stock. ImmunGene will use the capital to advance its early-stage development products to IND-enabling studies.

7 Nov 2013

Immunocore achieves first milestone in major research and licensing agreement with GSK

Immunocore Limited, the Oxford-based biotechnology company developing novel biological drugs to treat cancer and viral disease, today announced the achievement of its first milestone in its major research and licensing agreement with GlaxoSmithKline for multiple novel targets.

7 Nov 2013

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, announced results for the third quarter ended September 30, 2013.

6 Nov 2013

Brookdale Senior Living's total revenue increases $32.9 million in third quarter 2013

Brookdale Senior Living Inc. today reported financial and operating results for the third quarter of 2013.

6 Nov 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PDL BioPharma, Inc. announced today that it closed a financing transaction with Durata Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses.

6 Nov 2013

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

PhotoMedex, Inc. today reported financial results for the three and nine months ended September 30, 2013.

6 Nov 2013

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

ADC Therapeutics Sarl, a portfolio company of Auven Therapeutics and the oncology drug development company specializing in proprietary antibody drug conjugates, and Five Prime Therapeutics, Inc., a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.

6 Nov 2013

GSI Group generates revenue of $85.5 million during third quarter 2013

GSI Group Inc., a global leader and supplier of precision photonics and motion control components and subsystems to the medical, industrial, electronics and scientific markets, today reported financial results for the third quarter of 2013.

6 Nov 2013

WageWorks reports total revenue of $53.6 million for third quarter 2013

WageWorks, Inc., a leading provider of Consumer-Directed Benefits, such as pre-tax accounts for health, commuter and other employee benefits, today announced the Company's financial results for its third quarter ended September 30, 2013.

6 Nov 2013

DaVita HealthCare announces results for third quarter 2013

DaVita HealthCare Partners Inc. (NYSE: DVA) today announced results for the quarter ended September 30, 2013. Adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 was $211.0 million and $605.3 million, or $0.98 and $2.82 per share, respectively, excluding a loss contingency reserve. In addition, adjusted income from continuing operations attributable to DaVita HealthCare Partners Inc. for the nine months ended September 30, 2013 excluded a contingent earn-out obligation adjustment. Income from continuing operations attributable to DaVita HealthCare Partners Inc. for the three and nine months ended September 30, 2013 including these items was $136.6 million and $407.9 million, or $0.64 per share and $1.90 per share, respectively.

6 Nov 2013

Furiex reports financial and operating results for third quarter 2013

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) today reported its financial and operating results for the quarter ended September 30, 2013.

6 Nov 2013

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for the first quarter of Fiscal 2014 (ended September 30, 2013).

6 Nov 2013

Business / Finance

ERBA Diagnostics’ net revenues increase 83% to $6,941,000 in third quarter 2013

Cardioinsight completes long-term strategic financing to conclude multi-center clinical studies in Europe

Chindex International third quarter 2013 revenue increases 16% to $43.1 million

Lawnwood Regional Medical Center & Heart Institute buys first Renaissance system

ChinaSoft inks agreement with CITIC 21CN on Pharmaceutical Information Sharing Program

Genovate, ScinoPharm to jointly develop new-generation oral Hepatitis B drug Livepro

Covidien fourth quarter net sales increase 2% to $2.56 billion

China Cord Blood Corporation releases financial results for second quarter and first half of fiscal year 2014

ImmunGene secures $9 million in Series A financing from Ally Bridge Group

Immunocore achieves first milestone in major research and licensing agreement with GSK

Alliance HealthCare Services third quarter 2013 revenue decreases $2.6 million

Brookdale Senior Living's total revenue increases $32.9 million in third quarter 2013

PDL BioPharma closes financing transaction with Durata Therapeutics

PhotoMedex third quarter 2013 revenues decrease 19% to $45.9 million

ADC Therapeutics, Five Prime sign exclusive license agreement for human antibodies

GSI Group generates revenue of $85.5 million during third quarter 2013

WageWorks reports total revenue of $53.6 million for third quarter 2013

DaVita HealthCare announces results for third quarter 2013

Furiex reports financial and operating results for third quarter 2013

Bioniche Life Sciences announces financial results for first quarter of Fiscal 2014

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Latest News